@adamfeuerstein 6-month FEV1 data from VX-809 combo ph3 will impress and prove those who were skeptical based on '56 day' data WRONG.avidresearch (@avidresearch) January 2, 2014
@adamfeuerstein AMGN buys UCBSan (@LukatonMateo) January 5, 2014
The key issue for the FTC is whether the deal kills competition between Concert's treatment and Vertex's Kalydeco.
It's a wonder to me how split this market really is.
Here are Tuesday's top research calls, including new coverage of Adobe and Okta, a downgrade for Advanced Micro Devices and an upgrade for Chegg.